{Reference Type}: Journal Article
{Title}: Where Morphological and Molecular Classifications Meet: The Role of p53 Immunohistochemistry in the Prognosis of Low-Risk Endometrial Carcinoma (GLAMOUR Study).
{Author}: Puppo A;Fraternali Orcioni G;Clignon V;Musizzano Y;Zavattero CA;Vocino Trucco G;Benazzo GM;Vizzielli G;Restaino S;Mariuzzi L;Orsaria M;Seracchioli R;Raimondo D;Bertoldo L;Uccella S;Caliò A;Vittori Antisari G;Garzon S;Capozzi VA;Berretta R;Cosentino F;Ercoli A;Ieni A;Arcieri M;Ceccaroni M;Pesci A;Mantovani G;Bruni F;Roviglione G;Zeppa P;Raffone A;Camanni M;Delpiano EM;Provenza C;Borghese M;Migliaretti G;
{Journal}: Cancers (Basel)
{Volume}: 16
{Issue}: 6
{Year}: 2024 Mar 7
{Factor}: 6.575
{DOI}: 10.3390/cancers16061088
{Abstract}: No prospective study has validated molecular classification to guide adjuvant treatment in endometrial cancer (EC), and not even retrospective data are present for patients with morphological low-risk EC. We conducted a retrospective, multicenter, observational study including 370 patients with low-risk endometrioid EC to evaluate the incidence and prognostic role of p53 abnormal expression (p53abn) in this specific subgroup. Among 370 patients, 18 had abnormal expressions of p53 (4.9%). In 13 out of 370 patients (3.6%), recurrences were observed and two were p53abn. When adjusting for median follow-up time, the odds ratio (OR) for recurrence among those with p53abn versus p53 wild type (p53wt) was 5.23-CI 95% 0.98-27.95, p = 0.053. The most common site of recurrence was the vaginal cuff (46.2%). One recurrence occurred within the first year of follow-up, and the patient exhibited p53abn. Both 1-year and 2-year DFS rates were 94.4% and 100% in the p53abn and p53wt groups, respectively. One patient died from the disease and comprised p53wt. No difference in OS was registered between the two groups; the median OS was 21.9 months (16.4-30.1). Larger multicenter studies are needed to tailor the treatment of low-risk EC patients with p53abn. Performing molecular classification on all EC patients might be cost-effective, and despite the limits of our relatively small sample, p53abn patients seem to be at greater risk of recurrence, especially locally and after two years since diagnosis.